|
1
|
Rea D, Coppola G, Palma G, Barbieri A,
Luciano A, Del Prete P, Rossetti S, Berretta M, Facchini G, Perdonà
S, et al: Microbiota effects on cancer: From risks to therapies.
Oncotarget. 9:17915–17927. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tan J, McKenzie C, Potamitis M, Thorburn
AN, Mackay CR and Macia L: The role of short-chain fatty acids in
health and disease. Adv Immunol. 121:91–119. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
McNabney SM and Henagan TM: Short chain
fatty acids in the colon and peripheral tissues: A focus on
butyrate, colon cancer, obesity and insulin resistance. Nutrients.
9:13482017.doi: 10.3390/nu9121348. View Article : Google Scholar :
|
|
4
|
Davie JR: Inhibition of histone
deacetylase activity by butyrate. J Nutr. 133 Suppl:2485S–2493S.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hinnebusch BF, Meng S, Wu JT, Archer SY
and Hodin RA: The effects of short-chain fatty acids on human colon
cancer cell phenotype are associated with histone hyperacetylation.
J Nutr. 132:1012–1017. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ooi CC, Good NM, Williams DB, Lewanowitsch
T, Cosgrove LJ, Lockett TJ and Head RJ: Structure-activity
relationship of butyrate analogues on apoptosis, proliferation and
histone deacetylase activity in HCT-116 human colorectal cancer
cells. Clin Exp Pharmacol Physiol. 37:905–911. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tian Y, Xu Q, Sun L, Ye Y and Ji G:
Short-chain fatty acids administration is protective in
colitis-associated colorectal cancer development. J Nutr Biochem.
57:103–109. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fung KY, Brierley GV, Henderson S,
Hoffmann P, McColl SR, Lockett T, Head R and Cosgrove L:
Butyrate-induced apoptosis in HCT116 colorectal cancer cells
includes induction of a cell stress response. J Proteome Res.
10:1860–1869. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tang Y, Chen Y, Jiang H and Nie D: The
role of short-chain fatty acids in orchestrating two types of
programmed cell death in colon cancer. Autophagy. 7:235–237. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yu DC, Bury JP, Tiernan J, Waby JS, Staton
CA and Corfe BM: Short-chain fatty acid level and field
cancerization show opposing associations with enteroendocrine cell
number and neuropilin expression in patients with colorectal
adenoma. Mol Cancer. 10:272011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bindels LB, Porporato PE, Ducastel S,
Sboarina M, Neyrinck AM, Dewulf EM, Feron O, Lestavel S, Cani PD,
Staels B, et al: Ffar2 expression regulates leukaemic cell growth
in vivo. Br J Cancer. 117:1336–1340. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kondo Y and Issa JP: Epigenetic changes in
colorectal cancer. Cancer Metastasis Rev. 23:29–39. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Okugawa Y, Grady WM and Goel A: Epigenetic
alterations in colorectal cancer: Emerging biomarkers.
Gastroenterology. 149:1204–1225.e1212. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
An W, Kim J and Roeder RG: Ordered
cooperative functions of PRMT1, p300, and CARM1 in transcriptional
activation by p53. Cell. 117:735–748. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ryu JW, Kim SK, Son MY, Jeon SJ, Oh JH,
Lim JH, Cho S, Jung CR, Hamamoto R, Kim DS, et al: Novel prognostic
marker PRMT1 regulates cell growth via downregulation of CDKN1A in
HCC. Oncotarget. 8:115444–115455. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liao HW, Hsu JM, Xia W, Wang HL, Wang YN,
Chang WC, Arold ST, Chou CK, Tsou PH, Yamaguchi H, et al:
PRMT1-mediated methylation of the EGF receptor regulates signaling
and cetuximab response. J Clin Invest. 125:4529–4543. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tan CP and Nakielny S: Control of the DNA
methylation system component MBD2 by protein arginine methylation.
Mol Cell Biol. 26:7224–7235. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kim SK, Kim K, Ryu JW, Ryu TY, Lim JH, Oh
JH, Min JK, Jung CR, Hamamoto R, Son MY, et al: The novel
prognostic marker, EHMT2, is involved in cell proliferation via
HSPD1 regulation in breast cancer. Int J Oncol. 54:65–76.
2019.PubMed/NCBI
|
|
19
|
Kim K, Son MY, Jung CR, Kim DS and Cho HS:
EHMT2 is a metastasis regulator in breast cancer. Biochem Biophys
Res Commun. 496:758–762. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim DS, Ryu JW, Son MY, Oh JH, Chung KS,
Lee S, Lee JJ, Ahn JH, Min JS, Ahn J, et al: A liver-specific gene
expression panel predicts the differentiation status of in vitro
hepatocyte models. Hepatology. 66:1662–1674. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Son MY, Jung CR, Kim DS and Cho HS:
Comparative in silico profiling of epigenetic modifiers in human
tissues. Mol Biol Rep. 45:309–314. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jung KB, Lee H, Son YS, Lee MO, Kim YD, Oh
SJ, Kwon O, Cho S, Cho HS, Kim DS, et al: Interleukin-2 induces the
in vitro maturation of human pluripotent stem cell-derived
intestinal organoids. Nat Commun. 9:30392018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nebbioso A, Tambaro FP, Dell'Aversana C
and Altucci L: Cancer epigenetics: Moving forward. PLoS Genet.
14:e10073622018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yoshimatsu M, Toyokawa G, Hayami S, Unoki
M, Tsunoda T, Field HI, Kelly JD, Neal DE, Maehara Y, Ponder BA, et
al: Dysregulation of PRMT1 and PRMT6, type I arginine
methyltransferases, is involved in various types of human cancers.
Int J Cancer. 128:562–573. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kapral M, Wawszczyk J, Jesse K,
Paul-Samojedny M, Kusmierz D and Weglarz L: Inositol hexaphosphate
inhibits proliferation and induces apoptosis of colon cancer cells
by suppressing the AKT/mTOR signaling pathway. Molecules.
22:16572017.doi: 10.3390/molecules22101657. View Article : Google Scholar :
|
|
26
|
Tang Y, Chen Y, Jiang H and Nie D:
Short-chain fatty acids induced autophagy serves as an adaptive
strategy for retarding mitochondria-mediated apoptotic cell death.
Cell Death Differ. 18:602–618. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen J, Ding J, Wang Z, Zhu J, Wang X and
Du J: Identification of downstream metastasis-associated target
genes regulated by LSD1 in colon cancer cells. Oncotarget.
8:19609–19630. 2017.PubMed/NCBI
|
|
28
|
Luo CW, Wang JY, Hung WC, Peng G, Tsai YL,
Chang TM, Chai CY, Lin CH and Pan MR: G9a governs colon cancer stem
cell phenotype and chemoradioresistance through PP2A-RPA
axis-mediated DNA damage response. Radiother Oncol. 124:395–402.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sarris ME, Moulos P, Haroniti A,
Giakountis A and Talianidis I: Smyd3 is a transcriptional
potentiator of multiple cancer-promoting genes and required for
liver and colon cancer development. Cancer Cell. 29:354–366. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yamamoto I, Nosho K, Kanno S, Igarashi H,
Kurihara H, Ishigami K, Ishiguro K, Mitsuhashi K, Maruyama R, Koide
H, et al: EZH2 expression is a prognostic biomarker in patients
with colorectal cancer treated with anti-EGFR therapeutics.
Oncotarget. 8:17810–17818. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mathioudaki K, Papadokostopoulou A,
Scorilas A, Xynopoulos D, Agnanti N and Talieri M: The PRMT1 gene
expression pattern in colon cancer. Br J Cancer. 99:2094–2099.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hu H, Qian K, Ho MC and Zheng YG: Small
molecule inhibitors of rotein arginine methyltransferases. Expert
Opin Investig Drugs. 25:335–358. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Park J, Kim M, Kang SG, Jannasch AH,
Cooper B, Patterson J and Kim CH: Short-chain fatty acids induce
both effector and regulatory T cells by suppression of histone
deacetylases and regulation of the mTOR-S6K pathway. Mucosal
Immunol. 8:80–93. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pan P, Oshima K, Huang YW, Agle KA,
Drobyski WR, Chen X, Zhang J, Yearsley MM, Yu J and Wang LS: Loss
of FFAR2 promotes colon cancer by epigenetic dysregulation of
inflammation suppressors. Int J Cancer. 143:886–896. 2018.
View Article : Google Scholar : PubMed/NCBI
|
